Skip to main content

Home/ NPR-like radio blurb/ Contents contributed and discussions participated by Rowley Rice

Contents contributed and discussions participated by Rowley Rice

Simple Middle Filter: All | Bookmarks | Topics
1More

Proper dosage? - Washington Times - 0 views

washingtontimes.com/...20060612-093249-8415r Popular
shared by Rowley Rice on 17 Dec 09 - Cached
  • Rowley Rice on 17 Dec 09
     
    This popular source is an article from the Washington Times which discusses the problem of overmedication in the elderly. Interviews with doctors from hospitals across the country document the widespread issue. The elderly are often afflicted by many different conditions that require a diverse array of drug treatments. This often leads to drugs that combine for harsh side effects or which counter act each other. This was a very useful article in our blurb because it documents the problems that Mary Summer's husband experienced.
1More

Review of Tacrine Clinical Trials - 1 views

ageing.oxfordjournals.org/...161 review
shared by Rowley Rice on 28 Oct 09 - Cached
  • Rowley Rice on 28 Oct 09
     
    This article analyzes different clinical trials regarding the use of the drug tacrine (Cognex). Like several other of the review articles we marked, it allows us to evaluate the effectiveness of the different drugs and focus our project on examining the possibilities available for Alzheimer's treatment.
4More

Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidenc... - 1 views

www.annals.org/...379.long Review selected source
shared by Rowley Rice on 28 Oct 09 - Cached
  • The effectiveness of the 5 U.S. Food and Drug Administration–approved pharmacologic therapies for dementias in achieving clinically relevant improvements is unclear.
  • Purpose: To review the evidence for the effectiveness of cholinesterase inhibitors (donepezil, galantamine, rivastigmine, and tacrine) and the neuropeptide-modifying agent memantine in achieving clinically relevant improvements, primarily in cognition, global function, behavior, and quality of life, for patients with dementia.
  • Data Synthesis: 96 publications representing 59 unique studies were eligible for this review. Both cholinesterase inhibitors and memantine had consistent effects in the domains of cognition and global assessment, but summary estimates showed small effect sizes.
  • Rowley Rice on 28 Oct 09
     
    This March 2008 review article does an excellent job of analyzing the results of clinical studies on current Alzheimer's drugs. The article is an excellent review source because it analyzes data from 59 different studies. The purpose of the article is to examine the effectiveness of current Alzheimer treatments which are either cholinesterase inhibitors (donepezil, tacrine, galantamine, and rivastigimine) or NMDA receptor antagonists (memantine). The meta-analysis concludes that all the drugs show marginal symptomatic improvement and that there are no significant differences between them with regard to results. This is very useful to our project because it compares the effectiveness of different Alzheimer's drugs and our group's focus is on drug development.
3More

Alzheimer's Disease Drug Development in 2008 and Beyond: Problems and Opportunities - 1 views

www.ncbi.nlm.nih.gov/...PMC2570097 general info
shared by Rowley Rice on 28 Oct 09 - No Cached
  • To identify and counter risks we considered the relevance to AD drug development of the following factors: (1) effective dosing of the drug product, (2) reliable evaluations of research subjects, (3) effective implementation of quality controls over data at research sites, (4) resources for practitioners to effectively use CT results in patient care, (5) effective disease modeling, (6) effective research designs.
  • encountered in AD drug development can be avoided by changing practices. Current problems with human errors in clinical trials make it difficult to differentiate drugs that fail to evidence efficacy from apparent failures due to Type II errors.
  • Rowley Rice on 28 Oct 09
     
    Another article about the common reasons that Alzheimer's studies are flawed.
2More

BioMed Central | Full text | Changes in cognitive domains during three years in patient... - 2 views

www.biomedcentral.com/...7 primary selected source
shared by Rowley Rice on 28 Oct 09 - Cached
  • The objective was to identify separate cognitive domains in the standard assessment tools (MMSE, ADAS-Cog) and analyze the process of decline within domains during three years in Alzheimer's disease (AD) patients with donepezil treatment.
  • Rowley Rice on 28 Oct 09
     
    Review of patients treated with drug of dopenzil. Could be a primary source.
4More

BioMed Central | Full text | Recent developments in Alzheimer's disease therapeutics - 1 views

www.biomedcentral.com/...7 primary
shared by Rowley Rice on 28 Oct 09 - Cached
  • Therapeutic strategies aimed at preventing Aβ formation, blocking its aggregation into plaques, lowering its soluble levels in the brain, and disassembling existing amyloid plaques are among the main strategies employed to slow the progression of AD. Recently, a few therapeutic programs have aimed at reducing tau phosphorylation and/or aggregation. Beyond plaque- and tangle-related targets, other aspects of AD pathophysiology, including mitochondrial dysfunction, failure of molecular transport mechanisms, oxidative damage, inflammation, and cell-cycle dysregulation, may also provide therapeutic opportunities.
  • Tramiprosate is a glycosa
  • minoglycan mimetic that binds to monomeric Aβ, thereby reducing aggregation and neurotoxicity while promoting clearance from brain
  • Rowley Rice on 28 Oct 09
     
    This articles helpfully analyzes the different mechanisms of action that current AD drugs use. This was helpful for the more science-focused part of our project. To comment on AD treatment it was necessary to learn a basic understanding of how the drugs work inside the body. We found that they used the same receptor based mechanism of action that the drugs we studied in class used.
1More

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier) ... - 1 views

clinicaltrials.gov/...NCT00574132 primary
shared by Rowley Rice on 26 Oct 09 - Cached
  • Rowley Rice on 26 Oct 09
     
    Clinical trials overview for vaccine bapinezumab.
1More

Alzforum: News - 0 views

www.alzforum.org/...detail.asp popular
shared by Rowley Rice on 26 Oct 09 - Cached
  • Rowley Rice on 26 Oct 09
     
    This is a news blurb on the Alzheimer's Research Forum about the stopping of phenserine's release.
1 - 9 of 9
Showing 20▼ items per page